Get started
Author

Furha Cossor

Impact of chronic kidney disease on toxicity patterns and economic burden in CAR T-cell therapy for multiple myeloma: A national analysis.
2026 · Himil Mahadevia, Karnav Modi, et al. · Journal of Clinical Oncology · 1
Temporal evolution and demographic stratification of CAR T-cell therapy utilization for multiple myeloma in the United States: Insights from a National Inpatient Cohort (2017–2022).
2026 · Himil Mahadevia, Karnav Modi, et al. · JCO Oncology Practice
PDF
Temporal evolution and demographic stratification of CAR T-cell therapy utilization for diffuse large B-cell lymphoma in the United States: Insights from a National Inpatient Cohort (2017–2022).
2026 · Himil Mahadevia, Karnav Modi, et al. · JCO Oncology Practice
PDF
Clinical Impact of Acute Kidney Failure in Multiple Myeloma Patients Receiving CAR T-Cell Therapy: A National Inpatient Analysis
2026 · Himil Mahadevia, Karnav Modi, et al. · International Journal of Cancer Care and Delivery
PDF
Impact of Chronic Kidney Disease on Toxicity Patterns and Economic Burden in CAR T‑Cell Therapy for Multiple Myeloma: A National Analysis
2026 · Karnav Modi, Furha Cossor, et al. · International Journal of Cancer Care and Delivery
PDF
Impact of Chronic Kidney Disease on Adverse Event Topography and Economic Burden in CAR T‑Cell Therapy for DLBCL: A National Analyses
2026 · Himil Mahadevia, Karnav Modi, et al. · International Journal of Cancer Care and Delivery
PDF
The Impact of Acute Renal Failure on Treatment-Related Toxicity and Resource Utilization in Patients Undergoing CAR T‑Cell Therapy for Diffuse Large B‑Cell Lymphoma: A Nationwide Study
2026 · Karnav Modi, Furha Cossor, et al. · International Journal of Cancer Care and Delivery
PDF
AML-1080: Fludarabine/Melphalan vs Fludarabine/Busulfan Conditioning in AML Undergoing Allogeneic HCT
2026 · Aakriti Adhikari, Vasu Bansal, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: AML-1079: Pretransplant Measurable Residual Disease and Survival After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: Does Donor Type Change the Risk?
2026 · Aakriti Adhikari, Vasu Bansal, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: AML-1080: Fludarabine/Melphalan vs Fludarabine/Busulfan Conditioning in AML Undergoing Allogeneic HCT
2026 · Aakriti Adhikari, Vasu Bansal, et al. · Clinical Lymphoma Myeloma & Leukemia
AML-1079: Pretransplant Measurable Residual Disease and Survival After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: Does Donor Type Change the Risk?
2026 · Aakriti Adhikari, Vasu Bansal, et al. · Clinical Lymphoma Myeloma & Leukemia
Competing risks of relapse and major organ failure after allogeneic hematopoietic cell transplantation.
2026 · Aakriti Adhikari, Himil Mahadevia, et al. · Journal of Clinical Oncology
Differential clinical and economic signatures of CAR T-cell therapy in multiple myeloma across demographic and payer strata: A national analysis.
2026 · Karnav Modi, Himil Mahadevia, et al. · Journal of Clinical Oncology
Impact of geographic distance from transplant center on the risk of severe graft-versus-host disease after allogeneic hematopoietic cell transplantation.
2026 · Aakriti Adhikari, Vasu Bansal, et al. · Journal of Clinical Oncology
Impact of chronic kidney disease on adverse event topography and economic burden in CAR T-cell therapy for DLBCL: A national analysis.
2026 · Furha Cossor, Himil Mahadevia, et al. · Journal of Clinical Oncology
PDF
Differential clinical and economic signatures of CAR T-cell therapy in DLBCL across demographic and payer strata: A national analysis.
2026 · Karnav Modi, Himil Mahadevia, et al. · Journal of Clinical Oncology
Works count: 16
Citation count: 1
H-index: 1
I10-index:
Year
Topic
Type